INMD Stock Recent News

I upgrade InMode to Buy due to improved capital allocation, including significant share buybacks and potential for record dividends. Despite a 20% revenue decline in 2024, InMode remains a strong cash generator, with $600 million in cash. Conservative DCF valuation suggests a fair value of $21.67 per share, implying a 22.5% potential upside from current levels.

Three discounted MedTech stocks to gain from the market rebound are PAHC, FMS and INMD.

YOKNEAM, Israel , March 26, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer, and Yair Malca, Chief Financial Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Clarifies Capital Allocation Strategy and Commitment to Shareholder Returns Refutes Misconceptions on Staffing and Production Asserts No Justification for Additional Legal Action YOKNEAM, Israel , March 6, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital Management LLC ("DOMA") CEO and CIO Pedro Escudero in response to issues presented in his public letter dated January 15, 2025.

YOKNEAM, Israel , March 3, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in March: Barclays 27th Annual Global Healthcare Conference Presenters: Yair Malca, Chief Financial Officer  Format: In-person fireside chat moderated by Matt Miksic, Senior Equity Analyst, and one-on-one meetings Location: Miami, FL When: Wednesday, March 12 at 9:00 am EDT A live webcast of the presentation can be accessed here.

InMode is significantly undervalued, with strong cash flow, international expansion, and investments in research and marketing driving future revenue and free cash flow growth. The company benefits from the booming non-invasive plastic surgery market, expected to grow at a 14% CAGR from 2023 to 2030. INMD's stock repurchase program and substantial investments in bonds and bank deposits are expected to boost stock price and financial stability.

InMode Ltd. (NASDAQ:INMD ) Q4 2024 Results Conference Call February 4, 2025 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Technology Officer Yair Malca - Chief Financial Officer Rafael Lickerman - Vice President, Finance Conference Call Participants Danielle Antalffy - UBS Matt Miksic - Barclays Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Matson - Needham & Company Jeff Johnson - Baird Sam Eiber - BTIG Operator Good day, and welcome to the InMode Fourth Quarter and Full Year 2024 Earnings Results Conference Call.

Quarterly GAAP revenues of $ 97.9   million and full year revenue of $394.8 million Returned $285.4 million of capital to shareholders in full year 2024  Together with new 10% program, represents repurchase of approximately 27% of shares outstanding within 15 month timeframe, with the potential of substantial additional capital return in 2025 YOKNEAM, Israel, Feb. 4, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year 2024.

YOKNEAM, Israel , Feb. 3, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference in Snowbird, UT on Wednesday, February 12, 2025.